Tacrolimus-associated posterior reversible encephalopathy syndrome after kidney transplantation

Takamasa Ishiuchi, Masatoshi Takagaki, Hajime Nakamura, Shayne Morris, T Sakaki, Haruhiko KishimaInternational Journal of Case Reports and Images 2022 · DOI

Abstract

Calcineurin inhibitors are essential immunosuppressive agents for kidney transplant patients. Posterior reversible leukoencephalopathy syndrome (PRES) is a rare complication of treatment with calcineurin inhibitors. Herein, we report three cases of tacrolimus-associated posterior reversible leukoencephalopathy syndrome after kidney transplantation and their unique clinical courses. Patients in Cases 1 and 2 presented with headache and visual field disturbance on the fourth day after transplantation. Both patients were successfully treated with antihypertensive therapy and a change in medications from tacrolimus to cyclosporine and everolimus. Case 3 was a kidney transplant patient at 12 years post-transplant who developed fever and conjugate eye deviation to the right. The patient was initially treated with antihypertensive medication and a reduction in tacrolimus dose, but she experienced prolonged disturbance of consciousness, which eventually improved. These cases highlight the importance of considering the possibility of posterior reversible encephalopathy syndrome regardless of the time elapsed since transplantation.

Introduction

For kidney transplant recipients, Calcineurin Inhibitors (CNIs) such as Tacrolimus (TAC) are the gold standard for preventing organ rejection. However, these life-saving drugs are associated with a rare but severe neurological complication: Posterior Reversible Encephalopathy Syndrome (PRES).

PRES is a clinical-radiological syndrome characterized by headache, seizures, and visual disturbances, caused by vasogenic edema (fluid leakage) in the brain. If not identified and managed promptly, it can lead to permanent neurological damage or death via cerebral hemorrhage. Clinicians face a high-stakes balancing act: they must reduce or discontinue TAC to resolve the neurotoxicity while maintaining sufficient immunosuppression to prevent graft rejection.

Diagnostic and Therapeutic Approach

Diagnosis of PRES relies on a combination of clinical presentation and advanced neuroimaging. Magnetic Resonance Imaging (MRI) with Fluid-Attenuated Inversion Recovery (FLAIR) sequences is used to identify hallmark "high-signal" areas of brain edema. Magnetic Resonance Angiography (MRA) is typically performed to rule out permanent arterial occlusions or strokes.

Therapeutic strategies involve:

  1. Pharmacological Switch: Replacing TAC with a combination of Cyclosporine (another CNI) and Everolimus (an mTOR inhibitor).
  2. Dose Modification: Reducing the TAC dose or switching to extended-release formulations to minimize blood-level fluctuations.
  3. Blood Pressure Control: Using intravenous agents like Nicardipine to stabilize mean arterial pressure, as hypertension is a frequent exacerbating factor.

Case Series

Early-Onset PRES (Cases 1 & 2)

In the first two cases, patients developed symptoms—primarily headache and visual field disturbances—within the first week post-transplantation. MRI findings confirmed the presence of diffuse vasogenic edema characteristic of PRES.

MRI findings in early-onset PRES showing characteristic hyperintense lesions on FLAIR and subsequent resolution.

Following the immediate switch from TAC to a regimen of Everolimus and Cyclosporine, both patients experienced a full recovery of their vision. Follow-up imaging showed that the brain edema had completely resolved within months.

Late-Onset PRES (Case 3)

Case 3 presents a significant clinical outlier: a patient who had been stable for 12 years post-transplant before developing symptoms including fever and conjugate eye deviation. This patient was later diagnosed with Post-Transplant Lymphoproliferative Disorder (PTLD), which caused chronic diarrhea. It is hypothesized that the diarrhea increased the absorption rate of Tacrolimus, leading to a toxic spike that triggered the syndrome.

Neuroimaging for late-onset PRES showing vasogenic edema on CT and MRI, with MRA ruling out arterial occlusion.

Recovery in this case was more prolonged due to unstable TAC blood levels. However, by switching to an extended-release formulation and reducing the overall dose, the patient's neurological status and right-side vision loss (hemianopsia) improved over eight months.

Discussion

These cases provide several key insights into the management of CNI-induced neurotoxicity:

  • The "Late-Onset" Warning: While PRES is typically an early post-operative complication, Case 3 demonstrates that it can occur over a decade later. Clinicians must maintain a high index of suspicion for PRES throughout the life of the transplant.
  • Secondary Triggers: Physiological changes, such as diarrhea, can alter drug metabolism and absorption, potentially triggering toxicity even on a previously stable dose.
  • mTOR Inhibitors as a Safety Valve: Everolimus serves as a practical alternative to standard CNIs. mTOR inhibitors have a lower risk of neurotoxicity and can maintain immunosuppression while the brain recovers from CNI-induced damage.

Conclusion

Despite severe symptoms—including total blindness and hemiparesis—neurological symptoms in PRES are often reversible once the drug regimen is adjusted and blood pressure is controlled. While this case series highlights the efficacy of switching to mTOR inhibitors, further research is needed to establish formal guidelines for drug tapering versus immediate discontinuation in the context of PRES.

Summary updated

Abstract

Calcineurin inhibitors are essential immunosuppressive agents for kidney transplant patients. Posterior reversible leukoencephalopathy syndrome is a rare complication of treatment with calcineurin inhibitors. Herein, we report three cases of tacrolimus-associated posterior reversible leukoencephalopathy syndrome after kidney transplantation and their unique clinical courses. Patients in Cases 1 and 2 presented with headache and visual field disturbance on the fourth day after transplantation. Both patients were successfully treated with antihypertensive therapy and a change in medications from tacrolimus to cyclosporine and everolimus. Case 3 was a kidney transplant patient at 12 years post-transplant who developed fever and conjugate eye deviation to the right. The patient was initially treated with antihypertensive medication and a reduction in tacrolimus dose, but she experienced prolonged disturbance of consciousness, which eventually improved. These cases highlight the importance of considering the possibility of posterior reversible
BibTeX
@article{ishiuchi2022tacrolimus,
  author = {Takamasa Ishiuchi and Masatoshi Takagaki and Hajime Nakamura and Shayne Morris and T Sakaki and Haruhiko Kishima},
  title = {{Tacrolimus-associated posterior reversible encephalopathy syndrome after kidney transplantation}},
  journal = {International Journal of Case Reports and Images},
  year = {2022},
  doi = {10.5348/101297z01ti2022cs},
}
Figure